Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the operating margin high or low?
The operating margin of -28.23% is in line with its 5-year average of -26.03%, around the middle of its 5-year range (-214.34%–69.90%).
18.98% above its 12-month average of -34.84%.
Reported quarterly operating margin; no daily interpolation. Q2 FY2026 (2026-06-30): -39.70%.
OPERATING MARGIN
-28.23%
OPERATING MARGIN AVG TTM
-34.84%
OPERATING MARGIN AVG 3Y
-30.52%
OPERATING MARGIN AVG 5Y
-26.03%
OPERATING MARGIN AVG 10Y
-3.08%
OPERATING MARGIN AVG 15Y
N/A
OPERATING MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+18.98%
CURRENT VS 3Y AVG
+7.51%
CURRENT VS 5Y AVG
-8.46%
CURRENT VS 10Y AVG
-817.00%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.00%
median of 438 covered companies
CURRENT VS SECTOR MEDIAN
N/A
vs the sector median at left
Fulgent Genetics, Inc.
Market Cap
$637.59M
Operating Margin
-28.23%
TTM Avg
-34.84%
3Y Avg
-30.52%
5Y Avg
-26.03%
Market Cap
$642.31M
Operating Margin
-12.47%
TTM Avg
-13.07%
3Y Avg
-26.14%
5Y Avg
-20.95%
Market Cap
$643.37M
Operating Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$675.41M
Operating Margin
-187.24%
TTM Avg
-253932.81%
3Y Avg
-127981.70%
5Y Avg
-85456.42%
Market Cap
$596.36M
Operating Margin
-975.91%
TTM Avg
-867.04%
3Y Avg
-586.91%
5Y Avg
-743.36%
Market Cap
$579.88M
Operating Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$698.60M
Operating Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
| NAME | MARKET CAP | OPERATING MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Fulgent Genetics, Inc. (FLGT) | $637.59M | -28.23% | -34.84% | -30.52% | -26.03% |
| AngioDynamics, Inc. (ANGO)vs › | $642.31M | -12.47% | -13.07% | -26.14% | -20.95% |
| Climb Bio, Inc. (CLYM)vs › | $632.76M | 0.00% | 0.00% | 0.00% | 0.00% |
| Aura Biosciences, Inc. (AURA)vs › | $643.37M | 0.00% | 0.00% | 0.00% | 0.00% |
| 4D Molecular Therapeutics, Inc. (FDMT)vs › | $675.41M | -187.24% | -253932.81% | -127981.70% | -85456.42% |
| Aclaris Therapeutics, Inc. (ACRS)vs › | $596.36M | -975.91% | -867.04% | -586.91% | -743.36% |
| Annexon, Inc. (ANNX)vs › | $688.14M | 0.00% | 0.00% | 0.00% | 0.00% |
| BlossomHill Therapeutics, Inc. (BLSM)vs › | $579.88M | 0.00% | 0.00% | 0.00% | 0.00% |
| Faeth Therapeutics, Inc. (FTH)vs › | $698.60M | 0.00% | 0.00% | 0.00% | 0.00% |
| Aquestive Therapeutics, Inc. (AQST)vs › | $573.38M | -156.36% | -104.91% | -81.98% | -81.61% |
Gross Margin
35.6%
Operating Margin
-28.2%
Operating Margin = Operating Income / Revenue
Operating margin is the percentage of revenue remaining after operating expenses, reflecting operating efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | OPERATING MARGIN |
|---|---|
| 2026-06-30 | -39.70% |
| 2026-03-31 | -48.67% |
| 2025-12-31 | -43.48% |
| 2025-09-30 | -18.26% |
| 2025-06-30 | -24.10% |
| 2025-03-31 | -26.95% |
| 2024-12-31 | -21.17% |
| 2024-09-30 | -23.81% |
| 2024-06-30 | -26.62% |
| 2024-03-31 | -33.80% |
| 2023-12-31 | -214.34% |
| 2023-09-30 | 0.25% |
| 2023-06-30 | -29.18% |
| 2023-03-31 | -37.52% |
| 2022-12-31 | -53.99% |
| 2022-09-30 | 0.33% |
| 2022-06-30 | 10.21% |
| 2022-03-31 | 63.05% |
| 2021-12-31 | 59.94% |
| 2021-09-30 | 69.90% |
| 2021-06-30 | 64.38% |
| 2021-03-31 | 74.26% |
| 2020-12-31 | 76.59% |
| 2020-09-30 | 62.45% |
| 2020-06-30 | 15.29% |
| 2020-03-31 | -24.69% |
| 2019-12-31 | -4.88% |
| 2019-09-30 | 14.58% |
| 2019-06-30 | 3.50% |
| 2019-03-31 | -33.95% |
| 2018-12-31 | -18.12% |
| 2018-09-30 | -15.04% |
| 2018-06-30 | -18.54% |
| 2018-03-31 | -47.15% |
| 2017-12-31 | -48.35% |
| 2017-09-30 | -32.89% |
| 2017-06-30 | -3.23% |
| 2017-03-31 | 4.13% |
| 2016-12-31 | 21.51% |
| 2016-09-30 | -13.87% |
| 2016-06-30 | 24.43% |
| 2016-03-31 | -17.88% |
| 2015-12-31 | -253.15% |
| 2015-09-30 | 40.62% |
| 2015-06-30 | 34.20% |
| 2015-03-31 | 25.50% |
